Safe S.A. — Regulatory Filings 2020

Jan 12, 2021

PRESS RELEASE

Half-year report on the liquidity contract between Safe Orthopaedics and Louis Capital Markets

Eragny-sur-Oise, France, January 12th, 2021 - 18h00 CEST – Safe Orthopaedics (FR0013467123 - ALSAF), a company specializing in the design, manufacturing and marketing of single-use technologies for spinal surgeries, delivering the safest treatment for spinal fractures urgently treated, is today releasing its half-year report on the liquidity contract signed with Louis Capital Markets.

Under the contract, the liquidity account had the following holdings as of December 31st, 2020:

• 584 shares
• -35,87 euros

During the first half of 2020, the following have been negotiated:

PURCHASE	4,582 shares	1,803.84 euros	513 transactions
SALE	5,010 shares	1,947.17 euros	503 transactions

For the prior period (June 30th, 2020), the corresponding figures were:

• 1 012 shares
• 364,57 euros

As of March 18, 2019 (implementation of the new liquidity contract), the followings were made available:

• 74 738 shares
• 7 561,33 euros

Following the acquisition of Louis Capital Market|Midcap Partners by the group TPICAP Plc, the liquidity contract previously owned by Louis Capital Markets UK, LLP has been automatically transferred on 31/12/2020 to TP ICAP (EUROPE), the French entity of the group TPICAP, authorized and regulated by the French Autorité de Contrôle Prudentiel et de Résolution (ACPR) and the Autorité des Marchés Financiers (AMF).

The detail of day-to-day activities is as follows:

	Purchase			Sale
ALSAF FP	Trading volume	Number of shares	Cash (EUR)	Trading volume	Number of shares	Cash (EUR)
Total	513	4 582	1 803,84	503	5 010	1 947,17
20200701	4	59	29,32	1	1	0,50
20200702	3	38	18,60	6	101	51,73
20200703	5	75	36,77	5	60	31,07
20200706	1	1	0,52	9	158	82,22
20200707	4	71	35,64	5	62	32,71
20200708	4	57	28,40	2	21	10,75
20200709	4	56	27,30	1	1	0,49
20200710	5	65	30,90	1	1	0,48
20200713	2	14	6,45	5	71	33,60
20200714	3	35	16,15	4	56	26,75
20200715	4	55	25,63	1	1	0,48
20200716	2	15	6,90	4	56	26,41
20200717	1	1	0,48	5	67	32,33
20200720	5	75	35,28	2	12	5,82
20200721	3	38	18,30	1	1	0,49
20200722	1	1	0,49	6	119	59,14
20200723	5	58	28,61	2	21	10,67
20200724	4	32	15,39	1	1	0,49
20200727	3	22	10,49	11	202	105,98
20200728	4	51	24,87	5	57	28,71
20200729	4	51	24,84	2	2	1,00
20200730	4	46	22,17	4	50	24,93
20200731	4	39	18,42	1	1	0,47
20200803	3	24	11,50	2	21	10,29
20200804	4	18	8,48	4	56	27,10
20200805	5	22	10,26	2	21	10,11
20200806	2	4	1,88	2	221	103,02
20200807	4	25	11,59	2	19	9,01
20200810	5	21	9,67	3	30	14,25
20200811	1	1	0,69	11	145	100,76
20200812	8	57	28,86	2	15	7,95
20200813	7	48	22,87	1	1	0,49
20200814	5	32	14,45	6	78	36,63
20200817	5	37	17,21	2	16	7,65
20200818	4	24	10,95	3	21	9,87
20200819	4	24	10,78	2	9	4,14
20200820	6	41	17,55	1	1	0,45
20200821	4	22	9,22	1	1	0,43
20200824	1	1	0,43	4	44	18,81
20200825	2	5	2,07	2	14	5,88

PRESS RELEASE

20200826	3	19	7,84	3	22	9,30
20200827	4	24	9,88	3	22	9,35
20200828	2	10	4,09	4	41	17,23
20200831	4	27	11,03	2	9	3,76
20200901	6	46	17,69	1	1	0,39
20200902	4	23	8,62	1	1	0,38
20200903	1	1	0,38	4	44	16,77
20200904	1	1	0,38	3	22	8,35
20200907	5	38	13,90	5	56	21,47
20200908	3	23	8,61	6	67	26,80
20200909	5	45	16,75	4	36	14,04
20200910	3	26	9,47	6	60	22,71
20200911	4	35	13,11	1	1	0,38
20200914	4	32	11,85	4	36	13,86
20200915	4	32	11,84	1	1	0,37
20200916	1	1	0,37	4	39	14,56
20200917	3	27	10,04	1	1	0,37
20200918	3	21	7,78	1	1	0,38
20200921	4	30	10,94	4	40	15,20
20200922	3	25	8,88	4	39	14,39
20200923	4	32	11,52	3	20	7,39
20200924	4	32	11,37	4	39	14,31
20200925	4	34	11,90	2	8	2,87
20200928	2	9	3,18	6	72	26,55
20200929	4	36	12,65	5	48	18,14
20200930	3	25	8,97	2	10	3,69
20201001	1	1	0,35	2	10	3,55
20201002	6	63	21,69	1	1	0,35
20201005 20201006	5 10	50 92	16,52 37,69	11 5	125 50	45,09 22,08
20201007	3	25	9,55	6	71	28,12
20201008	5	52	20,68	1	1	0,40
20201009	11	100	35,72	1	1	0,36
20201012	7	53	18,56	1	1	0,36
20201013	1	1	0,35	3	31	10,80
20201014	1	1	0,34	1	1	0,34
20201015	4	29	9,77	1	1	0,34
20201016	2	10	3,36	1	1	0,34
20201019	2	10	3,34	3	32	10,89
20201020	6	42	13,84	1	1	0,33
20201021	5	33	10,38	4	53	17,23
20201022	5	37	11,35	1	1	0,32
20201023	7	45	13,31	2	4	1,23
20201026	11	62	17,45	4	54	16,54
20201027	9	49	12,47	2	21	5,66
20201028	10	58	13,41	1	1	0,24
20201029	7	35	7,37	2	21	4,60

PRESS RELEASE

20201030	5	25	5,13	10	161	35,23
20201102	1	1	0,23	9	134	30,66
20201103	2	15	3,47	7	90	21,59
20201104	4	47	11,26	5	53	13,10
20201105	10	119	27,56	4	41	10,20
20201106	1	1	0,25	11	135	33,90
20201109	5	66	16,25	4	33	8,59
20201110	5	62	15,00	2	12	3,00
20201111	3	29	6,97	2	15	3,69
20201112	2	19	4,57	4	39	9,64
20201113	2	20	4,83	2	15	3,69
20201116	1	1	0,25	9	94	24,39
20201117	3	32	8,28	5	37	10,01
20201118	6	77	19,84	2	11	2,96
20201119	3	30	7,55	1	1	0,25
20201120	4	43	10,59	4	38	9,75
20201123	1	1	0,26	4	39	10,14
20201124	2	20	5,03	3	30	7,74
20201125	3	32	7,97	3	30	7,72
20201126	3	27	6,72	4	41	10,57
20201127	1	1	0,25	4	33	8,39
20201130	2	21	5,29	2	13	3,34
20201201	1	1	0,26	11	101	27,90
20201202	1	1	0,29	4	25	7,13
20201203	4	53	14,42	5	29	8,67
20201204	3	34	9,24	2	10	2,80
20201207	4	51	13,61	4	27	7,54
20201208	4	55	14,82	4	31	8,62
20201209	5	66	17,37	1	1	0,27
20201210	5	65	16,94	3	24	6,46
20201211	1	1	0,27	1	1	0,27
20201214	1	1	0,27	7	81	21,61
20201215	4	52	13,61	11	103	28,68
20201216	4	58	15,18	9	77	21,66
20201217	1	1	0,28	11	85	24,37
20201218	5	81	22,10	6	40	11,43
20201221	4	58	15,33	11	77	21,63
20201222	1	1	0,35	11	63	22,21
20201223	1	1	0,90	11	44	39,60
20201224	11	74	75,07	6	11	12,20
20201225	0	0	0,00	0	0	0,00
20201228	0	0	0,00	0	0	0,00
20201229	10	136	89,82	0	0	0,00
20201230	9	119	63,52	11	31	18,72
20201231	10	121	81,71	1	1	0,69

Next financial release:

Annual 2020 results, January 14th, 2021 (post-market)

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company, a pioneer of the design and marketing of innovative ready-to-use technologies (single-use implants and instruments) for spinal fractures treatments. The company develops and manufactures kits combining sterile implants and single-use instruments, available at any time for the surgeon. These technologies enable minimally invasive approach, reducing the risk of cross contamination and infection, in the interest of the patient with a positive impact on hospitalization durations and costs. Protected by 17 patent families, the SteriSpineTM PS are CE marked and FDA approved. Safe Orthopaedics has its headquarters close to Paris (95610 Eragny-sur-Oise - France) has subsidiaries in the UK, Germany, United States and in the Lyon area where the manufacturing company is located. The Group employs around 150 employees.

For more information : www.SafeOrthopaedics.com

Contacts

Safe Orthopaedics

François-Henri Reynaud Chief Financial Officer Tél. : +33 (0)1 34 21 50 00 investors@safeorthopaedics.com

Press Relations

Ulysse Communication Pierre-Louis Germain / +33 (0)6 64 79 97 61 / plgermain@ulysse-communication.com Bruno Arabian / +33 (0)6 87 88 47 26 / barabian@ulysse-communication.com